

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1.-106. (Canceled)

107. (Currently amended) A method for modifying the fucosylation pattern of a recombinant glycopeptide comprising an acceptor, said method comprising:

contacting a full-length recombinant glycopeptide with a reaction mixture that comprises a fucose donor moiety and a fucosyltransferase under appropriate conditions *in vitro* to transfer fucose from the fucose donor moiety to the acceptor moiety, such that the glycopeptide has a substantially uniform fucosylation pattern;

wherein said acceptor moiety is Gal β 1,4GlcNAc-OR or NeuAc α 2,3Gal β 1,4GlcNAc-OR, wherein R is an amino acid, a saccharide, an oligosaccharide or an aglycon group having at least one carbon atom and is linked to or is part of a glycopeptide, and

wherein said eukaryotic fucosyltransferase is an isolated, recombinantly produced FucT-VI ~~corresponding to SEQ ID NO:1~~ or FucT-VII fucosyltransferase ~~corresponding to SEQ ID NO:2~~, and wherein said eukaryotic fucosyltransferase lacks a membrane anchoring domain, and wherein said fucosyltransferase provides at least 2-fold greater fucosylation of said glycopeptide than is achieved under identical conditions using isolated FucT-V.

108. (Currently amended) The method of claim 107, 115 or 117, wherein the concentration of said recombinant eukaryotic FucT-VI or FucT-VII fucosyltransferase is at least 1 Unit/ml.

109. (Currently amended) The method of claim 107, ~~or 108~~ 115 or 117, wherein the fucosyltransferase is FucT-VI.

110. **(Currently amended)** The method of claim 107, ~~or 108~~ 115 or 117, wherein the fucosyltransferase is FucT-VII.

111. **(Currently amended)** The method of claim 107, ~~or 108~~ 115 or 117, wherein said full-length recombinant glycopeptide is a clotting factor.

112. **(Previously presented)** The method of claim 111, wherein said clotting factor is selected from the group consisting of Factor VIII and Factor IX.

113-114. **(Canceled)**

115. **(Currently amended)** The method of claim ~~[[113]]~~ 107, wherein said isolated, recombinantly produced fucosyltransferase provides at least 4-fold greater fucosylation of said glycopeptide than is achieved under identical conditions using said isolated FucT-V.

116. **(Canceled)**

117. **(Currently amended)** The method of claim ~~[[113]]~~ 115, wherein said isolated, recombinantly produced fucosyltransferase provides at least 8-fold greater fucosylation of said glycopeptide than is achieved under identical conditions using said isolated FucT-V.

118. **(Canceled)**

119. **(Currently amended)** The method of claim 107, ~~or 108~~ 115 or 117, wherein said recombinant glycoprotein is present at a concentration of at least ~~about~~ 2 mg/ml.

120. **(New)** The method of claim 107, 115 or 117, wherein the concentration of said recombinant eukaryotic FucT-VI or FucT-VII fucosyltransferase is 50mU or less of said fucosyltransferase per mg of glycopeptide.

